Support for the approach of the Hessian institute, which is responsible for vaccine approvals in Germany, comes from Switzerland. There, experts also consider Stocker’s approach to be worthy of criticism.
Christoph Berger, President of the Federal Commission for Vaccination Issues (EKIF), shows understanding for the reaction of the Paul Ehrlich Institute. Because “the days when you mixed something together somewhere in the laboratory, which you then stab someone in the muscle, are definitely over,” he tells the Swiss tabloid “20 Minuten”. Stöcker did not proceed in a standardized manner in any way – neither in production nor in the tests.
“The way the recipe is formulated – it starts with ‘Man take …’ – fits a spaghetti recipe, but not for a vaccination that we subject test subjects to and from which we ultimately promise reliable protection,” he quotes Leaf to the President.
Criticism of the Stöcker approach comes from the Swiss Agency for Therapeutic Products, Swissmedic. “To protect all of us, the ethical principles and the evidence of scientific research are clearly regulated internationally,” said spokesman Lukas Jaggi to “20 Minuten”. In addition, observations, no matter how promising at first glance, must first be backed up with clinical data and control groups, he said. From his point of view, Winfried Stöcker “from good laboratory practice to good manufacturing practice to good clinical practice or due diligence in the Swiss Medicines Act strained pretty much everything that could be strained”, quoted him in “20 Minuten”.
Winfried Stöcker, former Euroimmun owner, developed a vaccine against corona and injected it into volunteers without any major clinical studies. According to “20 Minuten” he said that the vaccine could be produced for 8.6 million Swiss people within a few months.
You can read more news from Görlitz here.
Read more news from Niesky here.
–
